Drug Trial Radar · NCT01387737
Long-Term Safety Study of TA-7284 in Patients With Type 2 Diabetes Mellitus
Last checked: Nov 20, 2026Latest source record: Jan 8, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
1,299
Actual
Start
May 2011
Primary completion
Nov 2012
Study completion Dec 2012
Sponsor
- Lead sponsor
- Tanabe Pharma CorporationIndustry
- Sponsor type
- Industry
- First posted
- Jul 6, 2011
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Treatment
- Who can join
- All sexes, from 20 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The purpose of this study is to evaluate the safety and efficacy of TA-7284 as monotherapy or combination therapy with other oral anti-hyperglycaemic agent in Japanese patients with Type 2 diabetes mellitus on 52 weeks oral administration.
Conditions
- Type 2 Diabetes Mellitus
Interventions
TA-7284-LowDrug
TA-7284-Low
TA-7284-HighDrug
TA-7284-High
Primary outcomes
What the sponsor says the trial is designed to measure.
- Safety and Tolerability Assessed by Adverse Events, Hypoglycemic EventsTime frame: 54 weeks
Locations
7 sites in 1 country. Site status is shown where the registry gives one.
Research site
Chugoku, Japan
Research site
Hokkaido, Japan
Research site
Kanto, Japan
Research site
Kinki, Japan
Research site
Kyushu, Japan
Research site
Shikoku, Japan
Research site
Tōhoku, Japan
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.